- WEDNESDAY, MAY 26
- THURSDAY, MAY 27
Access! Award Presentation
The 2021 Champions of Access award honors those individuals and organizations who share AAM’s commitment to greater access to affordable, lifesaving and life sustaining medicines. We honor those who are similarly committed to ensuring that all patients can receive the medicine they need at a cost the system can bear.
FDA Commissioner Keynote Address
With patient access to generic and biosimilar medicines a national priority, it is important to communicate the U.S. Department of Health and Human Service’s key initiatives for the generic and biosimilars industry. FDA’s Acting Commissioner will share the latest agency actions on quality initiatives, supply chain integrity, inspections during COVID-19, GDUFA III and BsUFA III and innovation in the generic and biosimilars industry.
Janet Woodcock, M.D.
Acting Commissioner, Food and Drug Administration
Securing the Pharmaceutical Supply Chain
An in-depth discussion with key industry leaders, U.S. government officials, and recognized experts on the steps needed to secure the generic and biosimilar pharmaceutical supply chain. We will discuss lessons from previous supply chain disruptions to help create a stronger and more resilient U.S. supply chain, with a particular focus on COVID-19. In addition, panelists will discuss how the United States can become an increasingly important link in the global supply chain.
Table Setter: Meredith Broadbent
Senior Adviser, Center for Strategic and International Studies
Former Chair, International Trade Commission
Moderator: Jonathan Kimball
Vice President, Trade & International Affairs, AAM
Vice President, Supply Chain, North America, Novartis
Chief Executive Officer, Lupin Limited
President and Co-Chief Executive Officer, Amneal Pharmaceuticals
Deputy Assistant Secretary, Office of Strategy, Policy, Planning and Requirements (SPPR), U.S. Department Health and Human Services
Wash Reps Working Group (members only)
Law Committee (members only)
Access! 2021 Business Exposition
From the COVID Frontlines: Where Health and Politics Converge
A former United States Army Colonel, White House Coronavirus Response Coordinator and United States Global AIDS Coordinator, Deborah Birx, M.D., has answered her country’s call time and again. From experience, Dr. Birx knows how the arc from innovation to access changed the course of the biggest health challenges of our lifetime. Join AAM CEO, Dan Leonard, as he sits down with Dr. Birx for a frank conversation about lessons learned from a storied medical career that includes overseeing the President’s Emergency Plan for AIDS Relief (PEPFAR) to support HIV/AIDS treatment and prevention efforts across the globe, serving as U.S. special representative for global health diplomacy and for a time acting as the face of the federal government’s response to the COVID-19 pandemic.
Deborah Birx, M.D.
Former United States Army Colonel, White House Coronavirus Response Coordinator and United States Global AIDS Coordinator
President & CEO, AAM
Evolution and Disruption in Generic and Biosimilar Drug Channels
Join industry expert Adam J. Fein, PhD, as he helps you navigate this challenging and dynamic period in U.S. drug channels. During this interactive virtual session, Dr. Fein will explain the key trends reshaping U.S. drug channels, examine the emergence of organized market access channels, highlight business and marketing implications for generic and biosimilar medicines, and discuss strategic implications and the industry outlook. Dr. Fein will also be taking your questions during his session.
A message from Dr. Fein: https://www.youtube.com/watch?v=5D8qx1CQtfU
Adam Fein, PhD
CEO, Pembroke’s Drug Channels Institute
COVID-19 Impact on Generics: Trends, Issues, & Outlook
Join industry expert Doug Long, MBA, as he explores the continuing impact of COVID-19 on the U.S. pharmaceutical market and generics and biosimilars specifically. Among issue Doug will explore are reduced diagnosis visits, shifts in sites of care, acute vs. chronic prescriptions, specialty vs. traditional prescriptions and the lack of a 2020-2021 flu season. Doug will also look ahead for the rest of 2021 and beyond. He will take your questions during the session.
Vice President, Industry Relations, IQVIA
U.S. Biosimilar Market Access – Ensuring Current & Future Success
This panel will explore the current landscape for U.S. biosimilars. It will identify opportunities for policymakers to drive greater utilization and uptake under Medicare Part B, based in part on recent data revealing the impact of reimbursement rates and settings of care on prescriber behavior. The panel will look ahead to the coming expansion of biosimilars into Medicare Part D and discuss key policy changes that can encourage plans to promote their use.
Global Head of Biopharmaceuticals, Sandoz
Vice President, Policy, AAM
Associate Principal, Market Access Strategy Consulting, IQVIA
John Brooks, JD
Partner, South Capitol Consultants
Senior Director, Biosimilars, AmerisourceBergen
Policy Working Group (members only)
Access! 2021 Business Exposition
*Agenda is subject to change